Relmada Therapeutics Submits Further Allegations Against Laidlaw & Company

Leading biotechnology firm Relmada Therapeutics, recently announced that it intends to amend the original complaints that it made against Laidlaw & Company (UK) Ltd. In line with this, the company has filed a motion seeking to amend its original claims. The latest motion is part of a protracted legal battle between the pharmaceutical company and the financial services firm. The lawsuit is will be determined by the U.S. District Court for the District of Nevada.

The Amended Claims

Sources privy to the turn of events disclose that Relmada has can come up with additional claims pertaining to Laidlaw’s breach of its fiduciary duties. Apparently, the financial services provider used its position as Relmada’s investment banker to disclose crucial information to the public. Relmada is similarly seeking to be compensated for allegedly incurring high legal costs while defending itself against Laidlaw’s misleading and false proxy materials. Relmada asserts that Laidlaw’s actions are harmful and malicious. Despite being issued with a court order, the company has continued spreading malicious information concerning its takeover of Relmada.

About Laidlaw & Company

The financial services provider mainly focuses on wealth management and alternative investments solutions. It the firm prides itself for having the ability to provide comprehensive investment banking products and services to institutional clients and individuals. Its rich history, which spans more than 170 years has enabled it to consolidate its dominance in the industry.

Laidlaw has a burgeoning network of offices throughout the US and Europe. It recognizes that this is the best way that clients can have access to its services. The company has more than 150 employees who offer pragmatic financial advice. There is great emphasis on the development of an entrepreneurial work ethic within the structure of the firm. Laidlaw is led by a team of professionals who include CEO Mather D. Eitner, and James P. Ahern who is the Head of Capital Markets.